1. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I
2. Primary Hyperoxaluria
3. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
4. Maag, H. , Fernandes, M.X. , Zamboni, R. , Akbariromani, E. , Beaulieu, M.A. , Leblanc, Y. , and Thakur, P. (2020). Triazole glycolate oxidase inhibitors. World Intellectual Property Organization, WO2020010309A1. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020010309
5. Wang, B. , and Chao, Q. (2023). Glycolate oxidase inhibitors for the treatment of disease. US Patent and Trademark Office, US20230089374A1. https://patentcenter.uspto.gov/applications/17751144.